Liposomal mitoxantrone, venetoclax and azacitidine in relapsed/refractory acute myeloid leukaemia and early induction failure: a single-centre real-world study. [PDF]
Front OncolZhao J, Yang Y, Dai Y, Gao S, Tan Y.
europepmc +1 more source
Anthracycline and antimetabolite, trigger distinct resistance mechanisms in TP53<sup>mut</sup> AML. [PDF]
Cell Death DiscovRaghuwanshi S, Gartel AL.
europepmc +1 more source
Presenting a multi-marker response-adapted framework for venetoclax duration in acute myeloid leukemia. [PDF]
Ann HematolAdnan N.
europepmc +1 more source
Menin Inhibitors in Acute Myeloid Leukemia: Clinical Integration, Resistance, and the Path Beyond Monotherapy. [PDF]
Cancers (Basel)Zhang TY, Patel SA, Badar T.
europepmc +1 more source
Pirtobrutinib Monotherapy for First-Line Chronic Lymphocytic Leukemia: A Non-Anchored Indirect Comparison Using Reconstructed Patient-Level Data. [PDF]
Hematol RepMessori A +3 more
europepmc +1 more source
Venetoclax-Induced Symmetrical Drug-Related Intertriginous and Flexural Exanthema (SDRIFE): Implications for Diagnosis and Treatment Continuation. [PDF]
J DermatolTanaka N, Iso A, Higashime A.
europepmc +1 more source
FLT3-mutated AML: standards of care and ongoing investigation. [PDF]
Blood ResDo LV, Jorgensen JJ, Sahasrabudhe KD.
europepmc +1 more source
Novel targeted therapies for central nervous system involvement in chronic lymphocytic leukemia: A systematic review. [PDF]
Ther Adv HematolAl-Mashdali AF +3 more
europepmc +1 more source
Venetoclax with azacitidine and dexamethasone: Non-cytotoxic induction therapy for T-cell leukemia and mixed-phenotype leukemia. [PDF]
Ther Adv HematolLei Y +11 more
europepmc +1 more source
Functional heterogeneity of TP53 mutants in venetoclax-resistant AML: mechanisms, clinical implications, and therapeutic opportunities. [PDF]
Front OncolMaimaitituerhong M +8 more
europepmc +1 more source